Special Issue "Esophageal Cancer — Pathogenesis and Therapeutic Strategies"
Deadline for manuscript submissions: closed (15 December 2022) | Viewed by 2944
Interests: esophageal cancer; gastric cancer; neuroendocrine tumor; biomarkers; molecular epidemiology
Interests: endoscopy; endoscopic submucosal dissection; radiofrequency ablation; anti-reflux mucosectomy; endoscopic sleeve gastroplasty; per-oral endoscopic myotomy; esophageal cancer; Barrett’s esophagus; achalasia; colon cancer; reflux disease
Special Issues, Collections and Topics in MDPI journals
Interests: endoscopy; endoscopic ultrasound; esophageal cancer; molecular biology; translational study
Targeted therapies for esophageal cancer are important personalized treatments and may improve cancer outcomes. Previous studies and the genetic profiling of esophageal cancer have lead the treatment strategy from traditional chemoradiotherapy to immunotherapy. For poor responders to palliative chemotherapy, clinical trials on immune checkpoint inhibitors, targeting programmed death-1 (PD-1), PD-ligand 1 (PD-L1), or CTLA-4, have shown promising activity. Responders to immunotherapy may enjoy sustainable effects, but there is still no reliable biomarker to predict the response. Moreover, studies on esophageal carcinogenesis are ongoing, but the exact mechanisms behind it as well as the tumor microenvironment remain unclear.
In this Special Issue, we welcome original research and comprehensive review articles addressing the pathogenesis and potential targeted strategies of esophageal cancer to provide insights into clinical practice and future innovations. Researchers studying biomarkers, model systems, and preclinical or clinical trials using a targeted approach are invited to submit their work.
Dr. I-Chen Wu
Dr. Wen-Lun Wang
Dr. Wei-Lun Chang
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- esophageal cancer
- next generation sequence
- immune check point inhibitors
- targeting programmed death-1